No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination by Doris Heger-Mahn et al.
ORIGINAL RESEARCH ARTICLE
No Interacting Influence of Lavender Oil Preparation Silexan
on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel
Combination
Doris Heger-Mahn • Gu¨nther Pabst •
Angelika Dienel • Sandra Schla¨fke •
Christine Klipping
Published online: 16 October 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Purpose Silexan is an oral Lavender oil preparation with
proven anxiolytic efficacy. Given the high prevalence of
anxiety and restlessness in younger women, oral contra-
ceptives and Silexan will likely be co-administered.
Methods A double-blind, randomised, 2-period crossover
study was performed to investigate the effects of Silexan on
the pharmacokinetics and pharmacodynamics of Microgy-
non, a combination oral contraceptive containing ethinyl
estradiol 0.03 mg (EE) and levonorgestrel 0.15 mg (LNG) in
healthy, fertile, adult females. During 2 consecutive cycles
of 28 days, oral contraception was given for 21 days com-
bined with 1 9 160 mg/day Silexan or placebo. Plasma
concentration–time profiles of EE and LNG were obtained
on day 18 ± 1 up to 24 h after dosing. The primary outcome
measure was the area under the concentration–time curve
over a dosing interval of s = 24 h (AUCs) for EE and LNG
plasma levels. An interaction with Silexan was formally
excluded if the 90 % confidence interval for the AUCs ratio
during co-administration with Silexan or placebo was
included within the range of 0.80–1.25. Secondary outcomes
included EE and LNG peak concentration (Cmax) and time to
Cmax (tmax), follicle size, endometrial thickness, the Hoo-
gland score, and serum levels of estradiol, progesterone, and
sex hormone-binding globulin.
Results A total of 24 women (mean age 27.3 years; mean
body mass index 22.2 kg/m2) participated. The confidence
intervals for the EE and LNG AUCs and Cmax ratios fell
within the pre-specified limits, indicating no interaction
(point estimates [Silexan/placebo] AUCs EE 0.97, LNG
0.94; Cmax EE 0.99, LNG 0.96). For LNG, tmax was slightly
delayed. No secondary outcome indicated any impairment
of contraceptive efficacy.
Conclusions Co-administration of Silexan did not affect
the efficacy of a combination oral contraceptive containing
EE and LNG and was well tolerated.
Key Points
Due to the high prevalence of anxiety and restlessness in
younger women, the herbal anxiolytic drug Silexan and
oral contraceptives are likely to be co-administered.
Therefore, it is important to investigate the interaction
potential of Silexan with oral contraceptives.
This randomised, double-blind, placebo-controlled
crossover trial showed that Silexan did not relevantly
affect the pharmacokinetic properties of a
combination oral contraceptive containing ethinyl
estradiol and levonorgestrel.
Silexan therefore does not decrease the efficacy of
currently used combination oral contraceptives.
Trial registration: ISRCTN52706881, International Standard
Randomised Controlled Trial Number Register.
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1 Introduction
Silexan1 is a preparation from Lavandula angustifolia for
oral use that is obtained from the flowering tops of the plant
by steam distillation, and that complies with the monograph
Lavender oil of the European Pharmacopoeia [1] with
respect to all quality parameters. It exceeds the quality def-
inition of the pharmacopoeial monograph with respect to
items that are important for efficacy and tolerability. Ran-
domised controlled clinical trials have demonstrated that
Silexan is a potent anxiolytic drug with superior efficacy
compared with placebo in subsyndromal anxiety disorder
[2]. In generalised anxiety disorder (GAD), Silexan was
found to be comparably efficacious as lorazepam [3] and at
least as efficacious as paroxetine. The drug has a marketing
authorisation in Germany for the symptomatic treatment of
restlessness related to anxious mood, with a recommended
dosage of 80 mg/d. While Silexan is a complex, multi-
ingredient mixture, its anxiolytic properties have been
ascribed in particular to linalool and linalyl acetate [4].
Anxiety disorders are by far the most prevalent psy-
chiatric conditions in Western Europe and the USA [5, 6].
Their prevalence in women is at least twice as high as in
men [7, 8]. Since the prevalence of anxiety disorders tends
to decrease rather than to increase with age [9], a sub-
stantial proportion of the patients who seek treatment for
anxiety are women of childbearing potential who may be
practising oral contraception.
The steroid hormones contained in oral contraceptives
are metabolised mainly through hydroxylation in the liver.
Drugs that induce the cytochrome P450 (CYP) enzyme
system, notably CYP3A4, reduce the bioavailability by
increasing the first-pass metabolism of the oral contracep-
tive steroids and may therefore impair their efficacy,
leading to breakthrough bleeding and, possibly, unwanted
pregnancy [10, 11]. A comprehensive list of drugs that
induce CYP has been published by Rendic [12]. They
include several anticonvulsants and broad spectrum anti-
biotics, rifampicin, griseofulvin, and anti-retroviral drugs.
Bioavailability is the rate and extent to which the active
substance or active moiety is absorbed from a pharma-
ceutical form and becomes available at the site of action
[13]. As the use of herbal preparations increases in the
general population, the potential for herb–drug interactions
also increases. Therefore, herbal products must be assessed
for their efficacy and safety, including their potential for
interactions with other drugs [14]. Since women of child-
bearing potential who practise oral contraception represent
an important part of the target population for which Silexan
is intended, it is important to investigate whether the herbal
drug may have an effect on the bioavailability and efficacy
of oral contraceptives. Although a clinical study showed no
induction of the CYP enzymes 1A2, 2C9, 2C19, 2D6 and
3A4 [15], suggesting that no increased activity in metab-
olization of contraceptive ingredients occurs during co-
administration of Silexan, some examples of inhibition of
phase-II enzymes, mainly UDP-glucuronosyltransferases
(UGTs), by co-administered herbal drugs (e. g., Williams
et al. [16]) do exist. This study was therefore performed to
investigate the relative bioavailability of ethinyl estradiol
(EE) and levonorgestrel (LNG), the active ingredients of
the monophasic combination oral contraceptive Microgy-
non, during co-administration of Silexan as compared
with the administration of the oral contraceptive alone, as
well as any attenuating effect on contraceptive efficacy.
2 Experimental Procedures
2.1 Protocol and Design, Objectives
The investigation was performed as a double-blind, ran-
domised, placebo-controlled, monocentric, crossover study
in healthy volunteers whose primary objective was to
assess the interacting potential of Silexan with the phar-
macokinetic properties of EE and LNG, the active ingre-
dients of the combination oral contraceptive Microgynon.
An important secondary objective was to assess whether
Silexan had an effect on the suppressive efficacy of Mi-
crogynon on hormonal and ovarian status.
The protocol was reviewed and approved by an inde-
pendent ethics committee. All subjects provided written
informed consent. The principles of Good Clinical Practice
and the Declaration of Helsinki were adhered to.
2.2 Participants
The study participants were healthy, female, premenopau-
sal volunteers aged between 18 and 38 years (smokers had
to be B30 years of age, and those with a consumption of
more than ten cigarettes per day were excluded), who
presented with a body mass index between 18 and 30 kg/
m2. For eligibility for randomised treatment, subjects had
to take Microgynon for at least 2 cycles before ran-
domisation, with a ‘usual’ 28-day pill cycle and withdrawal
bleedings during the 7-day pill-free interval. Eligible sub-
jects were also required to use a non-hormonal method of
contraception in addition to Microgynon throughout the
study period. Women with delivery, abortion, or lactation
within 3 months of the study were excluded.
During study participation, the subjects were not
allowed to take any of the following drugs: any drugs
known or discussed to potentially induce liver enzymes
1 Silexan is the active substance of Lasea, manufacturer: Dr.
Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
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(e.g. rifampicin, dexamethasone, barbiturates, anticonvul-
sants, St. John’s wort); any drugs known to inhibit
CYP3A4 (e.g. ketoconazole, verapamil, cimetidine, mac-
rolides); any broad-spectrum antibiotics; and long-acting,
injectable or implant hormonal therapy within 26 weeks
prior to the screening visit, as well as any oral contracep-
tives other than the investigational treatment.
2.3 Interventions, Blinding
Silexan was presented in immediate-release soft gelatine
capsules containing 160 mg of lavender oil. An identically
matched placebo was available in which the smell of the
study drug was concealed by flavouring the capsules with
0.08 mg of Lavender oil, i.e., with 1/2000 of the amount of
Lavender oil contained in the active capsules. During
randomised treatment, the subjects had to take one capsule
of Silexan or placebo per day in the morning unchewed. A
daily dose of 160 mg corresponds to twice the currently
recommended dose of the marketed product. Moreover,
Silexan 160 mg/day has been shown to be highly effica-
cious in patients with GAD [17].
Microgynon is a combination oral contraceptive con-
taining 0.03 mg of EE and 0.15 mg of LNG in a coated
tablet. The drug is widely used in combination oral con-
traceptive interaction studies [18, 19] and was packed in
the original marketed package, which carried an additional
label presenting the information required for use in a
clinical trial. Starting on the first day of each cycle during
study participation, subjects were instructed to take one
coated tablet per day in the morning for 21 consecutive
days, followed by a 7-day break; during this break, the
administration of Silexan or placebo continued.
The study participants had to complete at least 2 cycles of
oral contraception with Microgynon in order to achieve
steady state conditions. Since LNG highly binds to sex
hormone-binding globulin (SHBG) in plasma, and EE
induces the SHBG binding capacity, LNG levels were
expected to be in a steady state after 2 cycles. Eligible sub-
jects were then randomised to 2 additional cycles with co-
administration of Silexan during the first and placebo during
the second cycle, or vice versa (Table 1). Double-blind
treatment was always started on the first day of the pill cycle
following randomisation. Treatment compliance was moni-
tored by recording each drug intake in a diary as well as by
counting the unused medication. Furthermore, plasma levels
of linalool, the main metabolite of Silexan, were determined
at weekly intervals during randomised treatment.
2.4 Study Schedule, Outcomes
During randomised treatment, weekly visits were scheduled
on days 7, 14, 21, and 28 of each cycle. For each visit, a
deviation of ±1 day was permitted. In addition, blood
sampling for determining the pharmacokinetic (PK)
parameters of EE and LNG was performed on 4 consecutive
days starting on day 18 ± 1 day of each cycle: on each of
these days EE and LNG trough levels were determined.
Furthermore, blood samples for determining PK profiles
were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after the
intake of Microgynon on the third and into the fourth day.
The subjects were required to abstain from any food and
beverages except for water after 22:00 h on the 2nd day of
sampling and received standardised meals on the 3rd day.
After the end of the 2nd cycle during randomised treatment, a
follow-up examination was scheduled to be performed
within 7–14 days. The samples were analysed for the
determination of EE, LNG, and linalool levels using a vali-
dated high-performance liquid chromatography (HPLC)–
tandem mass spectrometry (MS/MS) method and ConCalc
for Windows (CCW; Integ GmbH) software version 1.15.
The primary outcome measures for assessing potential
pharmacological interactions between Silexan and the
combination oral contraceptive were the area under the curve
over a dosing interval of s = 24 h (AUCs) derived from the
24-h concentration–time curves for EE and LNG at steady
state. Secondary outcome measures included the EE and
LNG peak concentration (Cmax), time to peak concentration
(tmax), and trough levels. Ovarian follicle size measurements
were performed through transvaginal ultrasound examina-
tions at screening and at each weekly visit during randomised
treatment, and the Hoogland score [20] was determined for
each treatment cycle as a measure of ovarian activity. SHBG
levels were determined at the end of the 3rd week (i.e., end of
Microgynon intake) during each cycle.
Assessment of safety and tolerability was based on
spontaneous reports of adverse events (AEs), physical
examinations and safety laboratory measurements.
2.5 Random Sequence Generation, Allocation
Concealment, Implementation
After subjects were determined as eligible for the trial, they
were randomised to treatment with Silexan followed by
placebo, or vice versa, at a ratio of 1:1. Fixed block ran-
domisation was used; however, the investigator was not
informed about the random block size until completion of
the trial. A biometrician otherwise not involved in the trial
generated the code using a validated computer program.
Upon inclusion into randomised treatment, each subject
received the lowest available number.
2.6 Statistical Methods, Sample Size
PK parameters were derived by non-compartmental meth-
ods using Phoenix WinNonlin software (Certara, L.P., St
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Louis, MO, USA). Cmax and tmax were read directly from
the data, the AUCs was derived by the linear trapezoidal
rule, t = (ln 2)/kz, where the terminal rate constant was
derived by log-linear regression, apparent clearance CL/
f = AUCs/dose, and apparent volume distribution Vz/
f = kz 9 CL/f/kz.
PK measures determined from the EE and LNG con-
centration-time profiles were compared between Silexan
and placebo using analysis of variance (ANOVA) models
with main effects for sequence, subject within sequence,
period, and treatment. Tests for AUCs and Cmax were
performed after log transformation, and for tmax on the
original untransformed scale. Confidence intervals deter-
mined on the log scale were back-transformed into the
original scale.
In the absence of other guidance, the assessment of the
pharmacological interacting potential of Silexan was based
on the same approach as when testing for bioequivalence
[21]: the absence of a clinically relevant PK interaction
between Silexan and EE or LNG was concluded if the
90 % confidence intervals for the AUCs ratios (Silexan/
placebo) determined from the ANOVA models were
included within the standard 80–125 % equivalence range.
Since the confidence intervals for the AUCs ratios of both
hormones were required to fall within the pre-specified
equivalence range simultaneously, type I error level
adjustment for multiple testing was not required.
Comparable ANOVA models were also applied to Cmax
and tmax; however, these were interpreted descriptively. For
SHBG concentration, an ANOVA model was fitted using
the same factors after log-transformation of the dependent
variable. All other interaction and safety measures were
evaluated using methods of descriptive data analysis.
The sample size estimation was based on the assumption
of a true within-subject coefficient of variation of 20 % for
ln(AUCs) of both EE and LNG. When the true AUCs ratio
between Silexan and placebo is between 0.95 and 1.05, a
sample size of 20 subjects will have at least 80 % power
for rejecting the null hypothesis predicting an interaction
between Silexan and EE or LNG according to the above
criteria. In order to compensate for study participants who
did not complete both treatment phases, a total of 24
subjects were to be randomised.
3 Results
3.1 Recruitment, Participant Flow, Protocol Deviations
Between November 2009 and May 2010, a total of 32
women were included and 24 were randomised and treated.
All randomised subjects completed the study as scheduled.
All treated subjects were analysed for safety. Two
subjects were excluded from all PK and pharmacodynamic
(PD) analyses; one took prohibited concomitant medication
and one missed one dose of Microgynon, which was
considered a major protocol deviation since it could not be
excluded that the dose might have been missed on the day
before obtaining the PK profile. One other subject mis-
takenly received the investigational treatments in reverse
order compared with the randomisation; however, she was
included into all analyses and evaluated as treated. All
decisions concerning the subjects’ eligibility for the dif-
ferent analyses were made before code breaking.
3.2 Sample Characteristics
The randomised study participants were aged between 21
and 37 years (mean ± standard deviation [SD] 27.3
± 4.1 years) and had a body mass index ranging between
19.3 and 26.8 kg/m2 (22.2 ± 2.0 kg/m2). All women were
fertile and had already used hormonal contraception before
inclusion. All participants were of Caucasian race,
although study participation was open to all ethnic groups.
Nine of the 24 women (37.5 %) were current smokers (up
to a maximum of ten cigarettes per day allowed) and seven
Table 1 Study schedule
Study period Screening: cycles
1 ? 2
Treatment: cycle 3 Treatment: cycle 4 Follow-up
Duration (days) Up to 56 28 28 7–14
21 7 21 7
Treatment Microgynon Microgynon ? SIL or
PL
SIL or PL Microgynon ? PL or
SIL
PL or SIL None
PK profile blood
samplesa
Days 3 ? 4 Days 3 ? 4
EE ? LNG trough
levels
Days 18–21 Days 18–21
a Samples were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after intake of Microgynon
EE ethinyl estradiol, LNG levonorgestrel, PK pharmacokinetics, PL placebo, SIL Silexan
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(29.2 %) were ex-smokers; 23 (95.8 %) drank alcohol
occasionally. The most frequent diseases in medical history
were myopia (ten subjects, 41.7 %) and headache (eight
subjects, 33.3 %). In the physical examination performed
at screening, none of the randomised subjects presented
with findings from which an inference with the study
procedures or outcomes was to be expected. Of note, none
of the women had abnormal findings in the gynaecological
examination.
3.3 Treatment Compliance
According to capsule counting, compliance with Silexan or
placebo was 100 % in 23 of the 24 subjects. One woman
took one additional capsule during the first treatment per-
iod and left out one during the second. The analysis of
linalool plasma concentrations confirmed that all partici-
pants had taken Silexan according to the randomisation,
whereas the treatment sequence had been mixed up in one
woman.
Of the 24 randomised participants, 22 took Microgy-
non as prescribed. One missed one dose (and was
therefore excluded from all PK and PD analyses),
whereas another woman took one additional dose while
under co-medication with placebo (by mistake two tab-
lets at once).
3.4 Pharmacokinetic and Pharmacodynamic
Evaluation
Figure 1 shows the plasma concentration–time profiles for
EE and LNG during co-administration of Silexan or pla-
cebo. The numerical results are presented in Table 2.
For EE and LNG, the 90 % confidence intervals for the
AUCs and Cmax ratios between Silexan and placebo were
completely included in the pre-specified equivalence
range so that an influence of co-administration of Silexan
on these PK measures could be excluded. Whereas the
results do not indicate a significant influence of Silexan
on tmax of EE, the tmax of LNG was prolonged by an
average of about 17 min (point estimate for the mean
value difference), albeit without significantly affecting
Cmax or the AUCs.
The results for the main PD outcomes and biomarkers
are summarised in Table 3. The only case of an active
follicle-like structure ([13 mm follicular growth accom-
panied by estradiol production) was observed during
placebo treatment. Average follicle sizes decreased dur-
ing Microgynon intake until day 21 but showed an
increase during the pill-free 4th week of the cycles.
Mean values were similar under co-medication with
Silexan and placebo; however, at three of the four post-
baseline visits, the larger average for both follicles was
observed during placebo treatment. Mean endometrial
thickness was also comparable during both treatment
phases.
Comparable mean levels for progesterone, estradiol, and
SHBG were observed during both treatment phases
(Table 3). Whereas progesterone showed only minor
changes over time, estradiol decreased markedly until the
end of the 2nd week of the cycles and continued to
decrease slightly during the 3rd week, whereas a sharp
average increase was observed in the pill-free 4th week.
During the first 3 weeks of each cycle, while administering
Microgynon, none of the women showed an estradiol
level [50 pg/ml, and one woman had a progesterone
level [3 nmol/l on day 21 while under co-administration
of placebo.
Individual values for the linalool concentrations indicate
that the PK evaluation has been performed after a steady
state was reached.
3.5 Safety/Tolerability
During randomised treatment, 36 AEs were reported by 17
of the 24 women (70.8 %) under co-administration of
Table 2 Main pharmacokinetic parameters (n = 22)
AUCs (pg 9 h/ml)a Cmax (pg/ml)
a tmax (h)
b
Ethinyl estradiol Placebo 937.4 ± 265.8 105.6 ± 33.2 1.5 (1.0–3.0)
Silexan 911.7 ± 263.3 106.6 ± 38.3 1.5 (0.9–3.0)
Ratio or difference 90 % CI 0.97 (0.93–1.02) 0.99 (0.92–1.07) 0.11 (-0.15 to 0.37)
Levonorgestrel Placebo 94.3 ± 34.6 8.0 ± 2.6 1.0 (0.5–1.6)
Silexan 90.3 ± 37.7 7.7 ± 2.8 1.1 (1.0–3.0)
Ratio or difference 90 % CI 0.94 (0.89–1.00) 0.96 (0.91–1.01) 0.29 (0.05–0.53)
a Mean ± SD, back-transformed CI for ratio between marginal (geometric) means from ANOVA model, Silexan/placebo
b Median (range), confidence interval for difference between marginal (arithmetic) means from ANOVA model, Silexan—placebo
ANOVA analysis of variation, AUCs area under the concentration–time curve over a dosing interval of s = 24 h, CI confidence interval, Cmax
peak concentration, SD standard deviation, tmax time to Cmax
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Microgynon and Silexan, whereas 23 events were repor-
ted by 16 subjects (66.7 %) in the Microgynon plus pla-
cebo phase. All events were mild or moderate in intensity,
and all were non-serious. AEs in which a causal relation-
ship to the investigational treatment could not be excluded
occurred in ten subjects during Microgynon and Silexan
treatment (gastrointestinal disorders, nine subjects; weight
increased, one subject; headache, two subjects; and acne,
one subject) as well as in two subjects during Microgynon
plus placebo treatment (headache and fatigue, one subject
each). Safety laboratory measures reflected changes that
were attributed to frequent blood sampling (e.g., anaemia)
but were otherwise uneventful.
4 Discussion
It is important to investigate whether anxiolytic drugs may
modify the bioavailability and the clinical efficacy of oral
contraceptives with steroid hormones.
The study demonstrates that Silexan does not show
clinically relevant pharmacological interactions with EE or
Fig. 1 Plasma concentration–
time profiles of EE (upper
panel) and LNG (lower panel)
over 28 days during treatment
with Microgynon plus placebo
and Microgynon plus Silexan
(mean ± SD). EE ethinyl
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LNG, which are the active ingredients of Microgynon as
well as of many other widely used oral contraceptives.
According to the lower bound of the 90 % confidence
intervals for the AUCs ratios of Silexan and placebo, a
reduction of relative EE bioavailability by more than 7 %,
as well as a reduction of relative LNG bioavailability by
more than 11 %, can be excluded with a probability of
95 %, and at least 92 % of the maximum EE concentration,
as well as 91 % of the maximum LNG concentration, are
preserved during co-administration of the herbal drug. For
LNG, a slight delay in reaching the LNG peak level was
observed, but this did not affect the relative bioavailability
of the hormonal contraceptives.
Smoking may alter the PK properties of oral contra-
ceptive steroids. Since about one-third of the women in the
study sample were mild smokers (subjects smoking more
than ten cigarettes per day were excluded from participa-
tion), this might have contributed to large inter-individual
variability in plasma concentrations, notably in EE. How-
ever, the inter- and intra-individual variability of the EE
plasma levels in our trial was comparable with the litera-
ture [22] and, moreover, higher variability would have
biased the data towards an acceptance of the null hypoth-
esis predicting an interaction between Silexan and EE and/
or LNG. Since the null hypothesis could be rejected and an
interaction could be excluded in accordance with the pre-
specified criteria, an introduction of bias due to the inclu-
sion of mild smokers can also be excluded.
Progesterone, estradiol, and SHBG level monitoring
also did not indicate an impairment of the contraceptive
efficacy of Microgynon during co-administration of Sil-
exan. Throughout the entire cycle of randomised treatment,
the average levels of these biomarkers during co-adminis-
tration of Silexan were always in the range of those
observed under placebo treatment.
Silexan had no appreciable effect on mean endometrial
thickness and follicle size. The measured individual follicle
sizes were always within the range expected during ade-
quate ovarian suppression [23], and a follicle size
exceeding a threshold value of 13 mm was observed only
once in a woman receiving placebo.
AEs observed during this trial in healthy volunteers
were never more than moderately severe and temporary;
abnormal laboratory values were more often related to the
study procedures (e.g., to frequent blood sampling) than to
study medication intake. Among the events assessed to be
potentially attributable to Silexan, the only effect that was
observed in more than one subject but also not during
placebo treatment was eructation. Mild gastrointestinal
disorders are among the known side effects of Silexan, but
were always tolerable and did not interfere with treatment
compliance.
In conclusion, Silexan, at a dose of 160 mg/day, corre-
sponding to twice the currently recommended dose, did not
adversely affect the relative bioavailability and the sup-
pressive efficacy on hormonal and ovarian status of the oral
combination contraceptive Microgynon whose active
ingredients are EE and LNG. Silexan was well tolerated.
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Table 3 Summary of main pharmacodynamic outcomes
Placebo Silexan
Hoogland score (n = 22)
No activitya 20 (90.9 %) 16 (72.7 %)
Potential activityb 1 (4.5 %) 6 (27.3 %)
Active follicle-like structurec 1 (4.5 %) 0 (0.0 %)
Follicle size, right (mm) (n = 22)
Day 7 7.1 ± 4.1 6.6 ± 2.0
Day 14 6.1 ± 3.6 5.0 ± 1.0
Day 21 5.1 ± 1.3 4.8 ± 0.8
Day 28 6.9 ± 1.5 7.3 ± 1.7
Follicle size, left (mm) (n = 22)
Day 7 6.4 ± 1.7 6.4 ± 2.1
Day 14 5.3 ± 1.0 5.0 ± 0.8
Day 21 4.9 ± 0.9 5.0 ± 0.8
Day 28 7.0 ± 1.9 6.7 ± 1.7
Endometrial thickness (mm) (n = 22)
Day 7 4.1 ± 1.1 4.4 ± 1.0
Day 14 4.0 ± 1.1 4.5 ± 1.5
Day 21 4.5 ± 1.8 4.1 ± 1.1
Day 28 3.6 ± 1.1 3.8 ± 1.2
Progesterone (nmol/l) (n = 24)
Day 7 1.2 ± 0.6 1.2 ± 0.6
Day 14 1.2 ± 0.6 1.1 ± 0.5
Day 21 1.1 ± 0.7 1.2 ± 0.6
Day 28 1.3 ± 0.7 1.3 ± 0.7
Estradiol (pg/ml) (n = 24)
Day 7 32.9 ± 114.6 31.2 ± 107.7
Day 14 8.1 ± 7.2 10.9 ± 6.6
Day 21 7.3 ± 6.0 7.5 ± 5.6
Day 28 44.9 ± 37.8 42.4 ± 32.0
SHBG (nmol/l) (n = 24)
Day 21 112.7 ± 40.0 113.5 ± 40.9
Data are presented as mean ± SD or number (%)
a Follicle size B10.0 mm
b Follicle size 10.1–13.0 mm
c Follicle size [13.0 mm, progesterone B5 nmol/l, estradiol [30 pg/
ml
SD standard deviation, SHBG sex hormone-binding globulin
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